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INTRODUCTION
Retinoblastoma (RB) is the most common intraocular (IO)
malignancy in children and it occurs almost exclusively in
young children less than 5 yr. The incidence is 1 in 15,000
to 30,000 live births in the United States (1). Though the
accurate incidence of RB in Korea is not known, it is estimated
to be about 20 to 40 per year according to the annual report of
the Korean Central Cancer Registry Program based on regis-
tered data from 131 hospitals. 
More than 80% of children with RB are cured with various
treatment modalities including enucleation (ENU), external
beam radiotherapy (EBRT), local therapy (LT), and chemother-
apy (CRx) (2). ENU has been the standard curative method
for advanced unilateral IO RB or for the more severely affect-
ed eye in a bilateral disease (3, 4). Despite the excellent sur-
vival of IO RB with simple ENU, it inevitably brings loss of
the globe and vision of the affected eye. EBRT can be used as
a primary treatment modality or adjuvant therapy after ENU
(5, 6). But it can cause many serious late complications includ-
ing cosmetic deformity and second malignancy (6-8). For these
reasons, there has been a substantial decrease in the frequen-
cy of ENU or EBRT over the recent decades, a great portion
of which is attributable to the advance in CRx and local treat-
ment modalities (9-17). However, there is still some debate
over the benefit of chemoreduction in advanced stage IO RB
and most published reports do not have the concept of adju-
vant CRx after LT. Therefore, we designed this pilot study to
investigate whether chemoreduction could reduce the size of
advanced IO RB enough to be treated by local modality, and
to investigate if adjuvant CRx might have a role in prevent-
ing relapse.
MATERIALS AND METHODS 
Patients
Nine consecutive patients (10 eyes) with advanced IO RB
were enrolled in Samsung Medical Center from March 2001 to
November 2001. Diagnosis was confirmed by typical clinical
presentation (leukocoria and/or strabismus) and ophthalmo-
logic examination. Ultrasonography of globes, neuroimaging
studies (CT or MRI), cerebrospinal fluid cytology, bone scan,
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Chemoreduction Followed by Local Therapy and Adjuvant 
Chemotherapy for Advanced Intraocular Retinoblastoma: 
A Pilot Study in a Single Center
Intraocular (IO) retinoblastoma (RB) has traditionally been treated with enucleation
(ENU) or external beam radiotherapy (EBRT). Recently, clinical trials are in progress
to cure RB without ENU or EBRT in order to salvage the globe and to avoid unac-
ceptable side effects of EBRT. We performed a pilot study to treat patients with
advanced Reese-Ellsworth (RE) stage IO RB with initial chemotherapy (CRx)
followed by local therapy (LT) and adjuvant CRx. Ten eyes (8 RE group V, 2 RE
group IV) from 9 patients were enrolled from March 2001 to November 2001. All
tumors responded to CRx. In 5 of 10 eyes, the RB was enough to be treated with
LT after chemoreduction. One patient who underwent LT is waiting for ENU due
to post-cryotherapy complication. For a median follow-up of 13 months (8-16 mo),
4 eyes that received LT and adjuvant CRx were relapse-free. A patient with bilat-
eral RB who failed to be a candidate for LT was rescued with high-dose CRx and
hematopoietic stem cell transplantation. Consequently, by treating patients accord-
ing to our strategy, we were able to salvage 6 out of 10 eyes without ENU or EBRT.
These results suggest that chemoreduction followed by LT and adjuvant CRx
might offer the opportunity to salvage the globe and vision even in patients with
advanced stage IO RB. 
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and bone marrow examination were done to define the tumor
size and extent. IO RBs were grouped according to the Reese-
Ellsworth (RE) classification. Tumor size was recorded as ‘tumor
base ×tumor thickness’ in millimeters. In the case where the
tumor was too large and almost filled the whole globe, the size of
each dimension was recorded as ‘over 20.00 mm’ and regard-
ed as 20.00 mm for the convenience of later comparison with
that of post-chemoreduction. 
Treatment
All 9 patients were initially treated with systemic CRx,
named ‘VEC’, including vincristine (1.5 mg/m2 i.v. on day 0),
etoposide (150 mg/m2 i.v. on day 0 and 1), and carboplatin
(560 mg/m2 i.v. on day 0). Informed consent was obtained
on every occasion before treatment. After 3 cycles of 3-week
interval CRx, the affected eye was thoroughly examined to
evaluate for objective reduction in tumor volume. Tumor
response was estimated as the percent reduction in tumor base
and thickness.
If objective reduction in tumor volume was achieved after
3 cycles of CRx, the same regimen was repeated for additional
3 cycles. After total 6 cycles of reduction CRx, the tumor was
reevaluated to decide on the next mode of therapy. In cases
where the tumor was reduced enough, we applied LT followed
by additional 3 cycles of adjuvant CRx. In cases where the
tumor was reduced but insufficient for LT, we added a few
cycles of the same regimen or more intensive CRx such as
‘CCG (Children’s Cancer Group) 321P2’ (cisplatin 60 mg/m2
i.v. on day 0, adriamycin 30 mg/m2 i.v. on day 2, etoposide
100 mg/m2 i.v. on day 2 and 5, and cyclophosphamide 30
mg/kg i.v. on day 3 and 4) and ‘ICE’ (ifosfamide 1,200 mg/m2
i.v. on day 0 to 4, carboplatin 400 mg/m2 i.v. on day 0 and 1,
and etoposide 100 mg/m2 i.v. on day 0 to 4) to increase the
tumor response. In our institution, only cryotherapy and
photocoagulation were available as LT modalities. EBRT was
excluded as a therapeutic tool in our protocol because of its
numerous late complications including cosmetic deformity
and second malignancy. 
After completion of treatment, patients were followed-up
by an ophthalmologist with an interval of less than 2 months
to monitor local recurrence.
Evaluation of treatment outcome and toxicities
Probability of event was estimated by the Kaplan-Meier
method. Event was defined as ENU (or decision to remove
the globe) or EBRT. 
Toxicities of CRx were recorded according to the common
toxicity criteria of National Cancer Institute of U.S.A..
RESULTS
Treatment outcomes
Table 1 summarizes patient characteristics and treatment
outcomes. Of 10 affected eyes in 9 patients (6 males and 3
females), 2 eyes were RE group IV and the other 8 eyes were
RE group V. One patient with bilateral RB was classified as
RE group IV and RE group V in each eye. None of the cases
had an extraocular disease. All 10 eyes showed objective reduc-
tion in tumor volume after CRx (Fig. 1, 2) but only 5 eyes
showed sufficient reduction of tumor volume for LT. There
1 M 69 L V VEC
� - 9 20.00×20.00 4.69×1.65 Yes Yes
¶ No 16
2 F 14 R V VEC - 6 16.32×9.95 6.03×2.50 Yes No Yes 16
3 M 10 R IV VEC - 6 10.61×5.05 9.99×3.37 Yes No Yes 14
4 M 21 R IV VEC CCG 321P2
� 13 17.28×7.23 14.42×2.82 No No
‖ Yes 13
L V 13 16.30×12.39 10.95×1.86 No No
‖ Yes 13
5 M 16 R V VEC CCG 321P2 11 15.80×20.00 11.74×2.94 No Yes No 13
6 F 17 L V VEC CCG 321P2 7 17.68×11.10 17.20×8.77 No No** No Lost 
→ICE
�
7 M 32 R V VEC - 6 20.00×20.00 16.65×3.75 No Yes No 10
8 F 34 R V VEC 6 15.81×14.07 9.95×3.50 Yes No Yes 9
9 M 24 R V VEC - 6 15.51×13.36 10.12×3.91 Yes No Yes 8
Patient
No.
Age
(mo)
Affected
Eye
RE
Group
CRx
Regimen
Regimen
Change
CRx
Cycles*
Local
Therapy
Final Vision
(Affected
Eye)
Follow-
up
(mo)
Table 1. Patient characteristics and treatment outcome
(base×thickness in millimeters)
Size
Initial After  CRx 
Sex Enucleation
RE, Reese-Ellsworth; CRx, chemotherapy.
*Total number of reduction chemotherapy. 
� Vincristine (1.5 mg/m2 i.v. on day 0), etoposide (150 mg/ m
2 i.v. on day 0, 1), carboplatin (560 mg/m
2 i.v.
on day 0). 
� Cisplatin (60 mg/m
2 i.v. on day 0), adriamycin (30 mg/m
2 i.v. on day 2), VP-16 (100 mg/m
2 i.v. on day 2, 5), cyclophosphamide (30 mg/kg
i.v. on day 3, 4). 
�Ifosfamide (1,200 mg/m
2 i.v. on day 0, 1, 2, 3, 4), carboplatin (400 mg/m
2 i.v. on day 0, 1), VP-16 (100 mg/m
2 i.v. on day 0, 1, 2, 3, 4).
¶We decided to enucleate the globe due to extensive retinal detachment after cryotherapy. 
‖A patient with bilateral disease is waiting for high-dose
chemotherapy and stem cell rescue due to lack of accessibility to either eye by local therapy. **Refused enucleation and lost to follow-up against
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was a median 29.3% (range, 2.7-76.6%) decrease in tumor
base and 75.0% (range, 21.0-91.8%) decrease in tumor thick-
ness. No tumor was sufficiently reduced enough to be a can-
didate for photocoagulation, so only cryotherapy was used as
LT because plaque radiotherapy was unavailable. Among the
5 patients (5 eyes) that entered into LT, one patient (Table 1,
Patient No. 1) had received additional 3 cycles (total 9 cycles)
of reduction CRx due to persistent retinal detachment, but we
decided to enucleate the globe due to extensive retinal detach-
ment that developed after cryotherapy. Ultimately, 4 of 10 eyes
with RE group IV or V achieved disease control by chemore-
duction and LT followed by adjuvant CRx and we were able
to preserve the globe and vision. Of the 5 eyes in which the
tumor volume was not reduced enough for LT, 2 eyes were
enucleated and one eye was lost to follow-up against medical
advice. The other 2 eyes in a patient with bilateral disease were
rescued with high-dose CRx and hematopoietic stem cell
transplantation because we could not access to either eye by LT
in spite of remarkable reduction in tumor volume and gain of
vision in both eyes. No patient received EBRT. Accordingly,
we could avoid ENU and EBRT and could preserve useful
vision in 6 out of 10 eyes in our cohort. Patients were followed
for a median of 13 months (range, 8-16 months). When we
define ‘event’ as ENU (or decision to enucleate) or EBRT, the
Kaplan-Meier estimate revealed 48.6% probability of event
at 16 months after chemoreduction (Fig. 3).
Of the 4 patients (5 eyes) who were not candidates for LT,
CRx regimen was changed in 3 patients (4 eyes)-due to per-
sistent retinal detachment in one patient with bilateral disease
(Table 1, Patient No. 4), poor response in the second case
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Fig. 1. Reduction of tumor size in base and thickness after chemotherapy. All 10 affected eyes responded to chemotherapy with variable
sensitivity. Tumor thickness seemed to be more dramatically reduced than tumor base after chemotherapy.
Fig. 2. Ultrasonographic finding of the globe in a patient with right intraocular retinoblastoma. Initial large intraocular mass (A) was dra-
matically reduced in size (B) after 6 cycles of VEC (vincristine, etoposide, and carboplatin) chemotherapy. 
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(Table 1, Patient No. 6), and lastly because the mass was too
near the optic disc to treat with LT (Table 1, Patient No. 5).
One patient who had received CRx as scheduled was finally
enucleated because the tumor showed insufficient response
and the initial total retinal detachment persisted even after
6 cycles of CRx
Toxicities of CRx
Table 2 summarizes the toxicities of CRx. There were no
treatment-related mortalities or serious life-threatening com-
plications attributable to CRx. Grade 4 leukopenia or throm-
bocytopenia was observed in some patients. All patients who
received more intensive CRx for the reasons previously de-
scribed were subject to grade 4 leukopenia but none of those
who received ‘VEC’ CRx suffered from severe leukopenia. Five
of 9 patients were subject to grade 4 thrombocytopenia but
there was no life-threatening bleeding episode. Three patients
required admission due to infectious complications, which
resolved completely after a short duration of intravenous antibi-
otics.
DISCUSSION 
Prior to entering this study, we had three important points
in mind in treating IO RB. First, we wanted to avoid ENU
that had been the most common treatment method of IO RB
because it might cause later psychotic problems in addition
to visual loss. Second, we decided not to use EBRT even in
cases where LT was impossible because of its serious compli-
cations including cosmetic deformity, which occurs in about
90% of patients, and other various late effects such as second
malignancy that would deteriorate the patient’s quality of life.
Third, we intended to make efforts to prevent recurrence or
metastasis because the prognosis of recurrent or metastatic RB
is generally poor with conventional treatment (18, 19). We
thought that CRx might increase the chance of globe salvage
potential and might reduce the probability of relapse as well. 
ENU is a relatively simple way of treatment and yields a
high cure rate. But as published by Ross et al., many patients
are more likely to show delays in visuomotor integration (20).
EBRT has been used as a method for saving the globe because
RB is generally a radiosensitive tumor. But little has been
known about the visual outcome after EBRT and it accompa-
nies many radiation-induced complications including cosmetic
deformity, cataract, retinopathy, glaucoma, vitreous hemorrhage,
optic neuropathy, keratopathy, and second malignancy in the
field of irradiation eventually leading to the loss of vision (6). 
In this background, we thought chemoreduction strategy
would give the patient an opportunity to live with his or her
‘own eye(s)’ and preserve useful vision in some patients. Until
now, the indications for chemoreduction in IO RB are not
clearly established. According to Friedman et al., small tumors
of RE group I to III were best treated with chemoreduction
strategy to avoid ENU and EBRT (13). However, they conclud-
ed that more effective therapy is required for RE group IV and
V. On the other hand, Gunduz et al. suggested that advanced
IO RB could also be treated well with chemoreduction followed
by various local treatment modalities such as photocoagulation,
cryotherapy, and plaque radiotherapy (12). However, tumors
may recur after LT. Because there are no reports that emphasize
the role of adjuvant CRx after LT to prevent RB from relapse,
we expect that our results would uncover the role of addition-
al adjuvant CRx in these patients after long-term follow-up. 
Of the local therapeutic modalities, plaque radiotherapy can
control relatively larger tumors up to 16 mm (21). However,
it is not available and most patients with RB are diagnosed at
an advanced IO stage in Korea. Therefore, the role of CRx is
much more important because the tumor size is a critical issue
for the success of cryotherapy or photocoagulation. Adjuvant
CRx is considered beneficial in this situation of limited local
therapeutic tools. Of the 5 eyes successfully treated with local
cryotherapy, 4 eyes did not show any sign of relapse. The other
one eye was eventually enucleated not due to recurrence but due
to retinal detachment as a complication of cryotherapy. Long-
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Fig. 3. Kaplan-Meier estimate of the probability of event. Event
was defined as enucleation (or decision to enucleate) or external
beam radiotherapy. Though patients had advanced stage intraoc-
ular retinoblastoma, none received external beam radiotherapy
and less than a half (48.6%) of the affected eyes were expected
to be ultimately enucleated according to our chemoreduction strat-
egy. All salvaged eyes had useful visions as well.
Grade 4 leukopenia 0/6 3/3
Grade 4 thrombocytopenia 3/6 2/3
Mean no. of RBC transfusion (range) 2.2 (1-4) 1.7 (0-3)
Mean no. of PLT transfusion (range) 2.5 (0-7) 4 (1-7)
Infection requiring admission 2/6 1/3
Treatment-related mortality 0/6 0/3
VEC* (n=6)     Intensive
�(n=3)
Table 2. Toxicities of chemotherapy
*Patients who received only VEC chemotherapy. 
� Patients who were
treated with more intensive regimen later.term follow-up is needed to uncover the benefits of adjuvant
CRx in this situation. 
This pilot study demonstrates that successful treatment of IO
RB is feasible with CRx, even in advanced group, if combined
with LT and adjuvant CRx. Though a proportion of patients
were not successfully treated with this protocol, at least disease-
progression was not observed in our patients. Our study is
limited due to the short follow-up period. However, Gallie
et al., who used 2 or 6 cycles of chemoreduction for IO RB,
demonstrated that relapse-free survival reached plateau at 1
yr after chemoreduction (9). We used a minimum of 6 cycles of
chemoreduction, which is a bit longer than in other pub-
lished reports. This was based on the concept that though
tumors respond dramatically during the first 2 or 3 cycles of
CRx and less thereafter, prolonged CRx might further reduce
the number of viable tumor cells even in cases where there was
no further reduction in tumor size, leading to reduced chance
of tumor recurrence after off-therapy. Adjuvant CRx after LT
can also be regarded as a portion of prolonged CRx in this con-
cept. Shields et al. used 6 cycles of chemoreduction before LT
and concluded that patients with RE group V required EBRT
in 47% and ENU in 53% with a median follow-up of 28
months (15). This result seems somewhat worse than that in our
patients considering that no patients received EBRT in our
patients. They used the same CRx regimen, or VEC, but their
interval between CRx was longer (4 weeks) than ours (3 weeks)
and they applied maximum 6 cycles of CRx compared with
minimum 6 cycles in our institution. Though our follow-up
duration is relatively short, we suppose that our prolonged and
compact CRx strategy might bring out superior results after
long-term follow-up. 
We changed CRx to more intensive ones in 3 patients (4 eyes)
who showed relatively insufficient responses after a minimum
of 3 cycles of standard CRx, but all 3 patients failed to enter
into LT. This suggests that early reduction potential is impor-
tant in foretelling the prognosis of globe salvage. On the basis
of the results in our pilot study, we are conducting another
pilot study using more intensive CRx regimen for the initial
treatment to see if more intensive CRx would bring out greater
reduction in tumor volume as well as in tumor necrosis leading
to increased chance of globe salvage. The pathology of 2 globes
ultimately enucleated revealed still viable tumor cells. It is yet
unknown whether more intensive CRx would lead to greater
tumor necrosis as well as greater reduction in tumor volume.
The results of intensive CRx in advanced IO RB will be pre-
sented later. 
In conclusion, we suggest that chemoreduction might be an
effective treatment strategy even in advanced IO RB provided
that proper LT and adjuvant CRx are combined. Long-term
follow-up might reveal the potential benefits of CRx such as
preventing metastatic or trilateral RB as well as preventing
relapse.
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